Evidence map›Paper›PMID 28431138›Full record

ArticleEuropean heart journal2019

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Patrick Rossignol, Rajiv Agarwal, Bernard Canaud, Alan Charney, Gilles Chatellier, Jonathan C Craig, William C Cushman, Ronald T Gansevoort, Bengt Fellström, Dahlia Garza and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Medical and advanced heart failure therapies in Türkiye.Turkish journal of medical sciences · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Chronic kidney disease impairs prognosis in electrical storm.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Beta-blockers in heart failure patients with severe chronic kidney disease-time for a randomized controlled trial?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Patrick RossignolInserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Université de Lorraine; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Institut lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, Nancy, France.
Rajiv AgarwalDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Bernard CanaudFresenius Medical Care Deutschland and University of Montpellier, UFR Medicine, France.
Alan CharneyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Gilles ChatellierAP-HP, Hôpital Européen Georges Pompidou, Unité de Recherche Clinique and INSERM CIC 1418, Paris, France.
Jonathan C CraigSchool of Public Health, The University of Sydney, New South Wales, Australia.
William C CushmanPreventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee, USA.
Ronald T GansevoortDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Bengt FellströmInserm U1018, Université Paris-Saclay, UVSQ, Université. Paris-Sud, Villejuif, France.
Dahlia GarzaRelypsa, Inc., Redwood City, CA, USA.
Nicolas GuzmanAstraZeneca, Gaithersburg, MD, USA.
Frank A HoltkampDutch Medicines Evaluation Board, Utrecht, The Netherlands.
Gerard M LondonF-CRIN INI-CRCT, Nancy, France.
Ziad A MassyF-CRIN INI-CRCT, Nancy, France.
Alexandre MebazaaF-CRIN INI-CRCT, Nancy, France.
Peter G M MolDutch Medicines Evaluation Board, Utrecht, The Netherlands.
Marc A PfefferCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yves RosenbergNational Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Luis M RuilopeInstitute of Investigation and Hypertension Unit, Hospital 12 de Octubre, Department of Preventive Medicine and Public Health, Universidad Autonoma and School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain.
Jonathan SeltzerACI Clinical, Bala Cynwyd, PA, USA.
Amil M ShahCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Salim ShahSarfez Pharmaceuticals, Inc., McLean, VA, USA.
Bhupinder SinghZS Pharma, San Mateo, CA, USA.
Bergur V StefánssonAstraZeneca, Gothenburg, Sweden.
Norman StockbridgeDivision of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Wendy Gattis StoughCampbell University College of Pharmacy and Health Sciences, NC, USA.
Kristian ThygesenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Michael WalshMcMaster University and Population Health Research Institute, Hamilton, Canada.
Christoph WannerDivision of Nephrology, Department of Internal Medicine 1, University Hospital Würzburg and Comprehensive Heart Failure Center, Würzburg, Germany.
David G WarnockDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Christopher S WilcoxHypertension, Kidney and Vascular Research Center and Division of Nephrology and Hypertension, Department of Medicine, Georgetown University, Washington, DC, USA.
Janet WittesStatistics Collaborative, Inc., Washington, District of Columbia, USA.
Bertram PittUniversity of Michigan School of Medicine, Ann Arbor, MI, USA.
Aliza ThompsonDivision of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Faiez ZannadInserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Université de Lorraine; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Institut lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, Nancy, France.

Funding

Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
NHLBI NIH HHS K24 HL152008
6 · The paper itself

Abstract

Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

Indexed as

Cardiovascular DiseasesCardiovascular SystemClinical Trials as TopicCreatinineHumansInterdisciplinary PlacementKidneyKidney Failure, ChronicPatient Care ManagementPatient SelectionRenal DialysisRenal Insufficiency, ChronicResearch DesignCreatinineCardiovascular diseasesChronic kidney failureChronic renal insufficiencyClinical trials as topic

Identifiers

PMID28431138
PMCPMC6657268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.